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Knowledge on charge-transfer complexes of drugs is important to understand the drug-receptor binding mechanism. 
Here, we have been synthesized the organic charge transfer complex of Benzimidazolium picrate (BP) and confirmed its 
molecular structure and carbon skeleton by 1H and 13C NMR spectral analysis. Asymmetric unit of BP consists of one 
benzimidazolium cation and a monovalent anion of picric acid. Decomposition pattern and thermal stability BP have been 
investigated using TG/DTA analysis. The interaction of the compound with calf thymus DNA is investigated by electronic 
absorption spectroscopy which indicates that the compound could interact with DNA through intercalation. The CT complex 
demonstrated significant free radical scavenging with 2,2-diphenyl-2-picryl-hydrazyl. The BP complex has been also 
screened for its antimicrobial activity. 
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All heterocyclic compounds have high significance in 
pharmaceutical chemistry. The benzimidazole moiety is 
bicyclic, consisting of fusion of benzene and imidazole, 
and is widely used in designing new drugs1. The 
benzimidazole derivatives represent one of the most 
biologically active class of compounds, possessing a 
wide spectrum of activities2,3. The benzimidazole 
nucleus has significance in medicinal chemistry, and 
many benzimidazole-containing compounds exhibit 
important biological activities viz. selective 
neuropeptide YY1 receptor antagonists, 5- lipoxygenase 
inhibitors for use as novel anti-allergic agents4, factor Xa 
(FXa) inhibitors5, poly (ADP-ribose) polymerase 
(PARP) inhibitors6 and as human cytomegalovirus 
(HCMV) inhibitors7. The structural resemblance of 
benzimidazole nucleus to biological compounds, such as 
the purine base of the DNA and the occurrence of this 
nucleus in vitamin B12 are of interest in pharmaceutical 
industry8-12. Benzimidazole constitutes an important 
group of electron donor or proton acceptor and the study 
of their charge transfer complex can help elucidate many 
chemical phenomena13-17. 
Proton or charger transfer complexes play an 
important role in the field of magnetic, electrical 
conductivity and optical properties18-22. The crystalline 
charge transfer complexes (CTCs) are known to have a 
vital role in biological systems such as antimicrobial 
activity and DNA-binding as well as in laser technology, 
optoelectronics, optical communications, photocatalyst, 
optical signal processing and dendrimer fabrication for 
drug delivery systems23-32. 
CT-interactions between aromatic electron 
acceptors and electron donors containing nitrogen, 
oxygen or sulphur atoms have been reported over the 
previous year33-36. Picric acid forms crystalline picrate 
salts with various organic molecules by virtue of its 
Lewis acid behaviour and serve as a better acidic 
ligand in the formation of salts through specific 
electrostatic or hydrogen bonding interactions37. 
Hence benzimidazole acts as the electron donor and 
picric acid acts as electron acceptor. Based on the 
above significance, sincere attempts were made for 
the successful synthesis of BP crystal. The current 
research work focuses on the UV-absorption and 
NMR characterisation, single crystal X-ray diffraction 
study of the BP crystal. In addition the DNA binding, 
antimicrobial activity and cleavage activities of the 
synthesised crystal were also investigated in detail. 




Materials and Methods 
All the chemicals used were chemically pure and 
are AR grade. Solvents were purified and dried 
according to the standard procedures38. Calf-thymus 
(CT-DNA) was purchased from Genei, Bangalore, 
India. Tetracycline, Nystatin and Agar were 
purchased from Hi-Media, Mumbai.  
 
Physical characterisation techniques 
Micro analyses (C, H and N) were performed on a 
Vario EL III CHNS analyzer at STIC, Cochin 
University of Science and Technology, Kerala, India. 
The IR spectrum was recorded employing KBr pellet 
method in the region of 400–4000 cm-1 using a 
PerkinElmer FTIR 8000 spectrophotometer. 
Electronic spectrum was recorded in methanol 
solution with a Systronics double beam UV–visible 
spectrophotometer 2202 in the range 200–800 nm. 1H 
and 13C NMR spectra were recorded on a Bruker AV 
III 500 MHZ instrument using TMS as an internal 
reference at SAIF, Indian Institute of Technology, 
Madras. Melting points were recorded with Veego 
VMP-DS heating table and are uncorrected. The 
thermal analysis (TG and DTA) were carried out 
under nitrogen atmosphere with a heating rate of 
20°C/ min by NETZCHSTA 409C analyzers. DNA 
cleavage study was carried out using Gelstan - Gel 
documentation system. Antioxidant study was carried 
out at the Kovai Medical Centre and Hospital 
Pharmacy College, Coimbatore, Tamil Nadu, India. 
 
X-ray crystal structure determination 
The crystallographic data of the complex has been 
measured at 298 K on a Bruker SMART APEX CCD, 
area detector system [λ (MoKα) =0.71073 Å]. A 
graphite monochromator, 2400 frames was recorded 
with an ω scan width of 0.3°, each for 10 s, crystal- 
detector distance 60 mm, collimator 0.5 mm. Data 
reduction was carried out by SAINPTUS39 and 
absorption correction was made using an empirical 
method SADBS40. The structure was studied and 
refined using SHELXL-9741. All non hydrogen is 
refined anisotropically. Cambridge Crystallographic 
Data Centre (CCDC No.1019637) contains the 
supplementary crystallo-graphic data for the complex. 
 
Synthesis of Benzimidazolium picrate (BP) complex 
Equimolar ratio of benzimidazole in methanol and 
picric acid in water were dissolved and mixed 
together. The solution was stirred well for about 2 h at 
room temperature using magnetic stirrer to ensure 
homogeneous mixture, filtered using Whatmann 41 
filter paper and kept aside unperturbed in a dust free 
room for the growth of single crystal. A good 
transparent needle shaped crystals was harvested in a 
growth period of 25-30 days. The purity of the 
synthesized crystal was further improved by repeated 
recrystallization process using methanol as solvent. 
(Scheme 1)  
 
Antioxidant behaviour 
The 2,2-diphenyl-2-picryl-hydrazyl radical 
scavenging activity of the compound was measured 
according to the method of Elizabeth & Rao42. The 
DPPH is a free radical having a stable λmax at 517 nm. 
A fixed concentration of the experimental compound 
(100 μL) was added to a solution of DPPH in 
methanol (0.3 mM, 1 mL) and the final volume were 
made up to 4 mL with double distilled water. DPPH 
solution with methanol was used as a positive control 
and methanol alone acts as blank. The solution was 
incubated at 37°C for 30 min in darkness. The 
decrease in absorbance of DPPH was measured at  
517 nm. The tests were run in triplicate and various 
concentrations (20-100 μg/ mL) of the compounds 
were used to fix a concentration at which the 
compounds showed 50% activity. In addition, the 
percentage of activity was calculated using the 
formula, % of suppression ratio = [(A0– Ac)/A0] X 100. 
Where, A0 and Ac are the absorbance in the absence 
and presence of the tested compounds, respectively. 
The 50% activity (IC50) can be calculated using the 
percentage of activity. 
 
DNA binding experiments 
The binding affinity of the compound with CT-
DNA was carried out in double distilled water with 
tris(hydroxymethyl)-aminomethane (Tris, 5 mM) and 
sodium chloride (50 mM). The pH was adjusted to 7.2 
using hydrochloric acid. A result of CT-DNA in the 
buffer gave a ratio of UV absorbance with reference 
to 1.8-1.9 at 260 and 280 nm, indicating that the DNA 
was suitably free of protein. The DNA concentration 
per nucleotide was determined by absorption 
spectroscopy using the molar extinction coefficient 
 
 




value of 6600 dm3 mol-1 cm-1 at 260 nm. The 
compound was dissolved in a mixed solvent of 5% 
DMSO and 95 % tris HCl buffer for all the 
experiments. Stock solutions were stored at 4°C and 
used within 4 days. Absorption titration experiments 
were performed with a fixed concentration of the 
compound (25 μM) with varying concentration of 
DNA (0-50 μM). While measuring the absorption 
spectra, an equal amount of DNA was added to all the 
test solutions and reference solution to eliminate the 
absorbance of DNA itself. 
 
Results and Discussion 
 
Elemental analysis 
The transparency and constituents of elements 
(CHN) of the synthesized complex were verified by 
the elemental analysis. The results shows that the 
compound BP contains C: 43.20 (44.97%), H: 2.12 
(2.61%), N: 19.91 (20.17%), O 31.25 (32.25%).The 
data analysed show that the experimentally obtained 
values are in good agreement with theoretical values 
(within the bracket). The result confirms the 
formation of the compound in stoichiometric 
proportion and the compound is free of impurities. 
 
IR spectra 
The characteristic vibrational frequencies of the 
functional group in the crystal lattice of BP are 
known through IR spectrum as shown in (Fig. 1) The 
formation of the charge transfer complex is strongly 
evidenced by the donor (picric acid) and acceptor 
(benzimidazole) molecules in the spectrum43,44. It is 
generally expected in acid – base interaction that 
there is a transfer of proton from the donor (acid) to 
acceptor (base). From the spectrum it is observed 
that the bands of the donor are slightly shifted to 
lower frequency and that of the acceptor are slightly 
shifted to higher frequency. This shift has been 
attributed to the charge transfer from the donor to 
acceptor upon the complexation.  The band observed 
at 3155 cm-1 is due to the N+-H stretching vibration. 
 
The absorption peak at 3663 cm-1 is due to the N-H 
asymmetric stretching vibration and corresponding 
symmetric stretching vibration is observed at 3093 cm-1. 
The aromatic C-H stretching vibration appears at 
3055 cm-1. The peak at 933 cm-1 is assigned to C-NO2 
stretching vibration. The frequencies at 1080 cm-1 is 
owed to C-H in plane bending vibration. The aromatic 
C=C stretching vibration is exhibited at 1604 cm-1. 
The peak at 1527 cm-1 is due to NO2 asymmetric 
stretching vibration and the corresponding symmetric 
stretching vibration band is observed at 1327 cm-1. 
The band is at 709 cm-1 owes to the aromatic C-H out 
of plane bending vibration. The C-O stretching vibration 
appears at 1256 cm-1. The NO2 scissoring and wagging 
vibrations are observed at 840 and 748 cm-1. 
 
UV-visible absorption spectra 
The optical absorption band is the most important 
parameter of the synthesised material for the 
implementation of various optical and biological 
applications. UV absorption spectra arise from the 
transition of electrons within a molecule from a lower 
electronic energy (LUMO) state to higher energy state 
(HOMO). When an atom or molecule absorbs the 
energy, electrons are promoted from their ground 
state to an excited state. The UV-visible absorption 
spectrum of the complex is shown in Fig. 2. The π-π∗ 
and n-π∗ transitions of BP appears 225 nm and  
268 nm, respectively .The change in the band is due 








Fig. 2 — Electronic absorption spectrum of Benzimidazolium picrate 
 




benzimidazole molecule to the acceptor picric acid 
molecule and appears on the longer wave length 
region. The charge transfer transition expected to 
occur in the longwave length region is gets 
submerged under the more intense   n-π∗ band. 
 
NMR spectra 
Molecular structure and carbon skeleton of BP 
crystals were confirmed by 1H and 13C NMR studies 
resulting from dissolution of crystalline BP in 
deuterated methanol are shown in Fig. 3 A and B, 
respectively. Six dissimilar proton signals appeared in 
the spectrum, confirming the presence of six different 
proton environments in the BP system. The downfield 
signal at 9.5 ppm corresponds to protons (H6 and 
H5A) of the picrate anion.  The most intense singlet 
peak at δ 8.9 ppm is assigned to the ring proton (H11) 
of the benzimidazolium moiety. The absence of any 
signal above δ 11 ppm impute to the phenolic proton 
confirming the existence of the picrate anion in 
solution through proton transfer mechanism. In the 
spectrum, the signals at δ 8.1 and (two H atoms 
attached to C13 and C8) and δ 7.9 ppm (two H atoms 
attached to C12 and C7) authenticate the presence of 
two sets of chemically equivalent protons in the 
aromatic ring of benzimidazolium moiety. 
A singlet signal at δ 5 ppm is attributed to the -
NH protons of benzimidazolium moiety in the BP 
complex. The carbon signal appeared in the upfield 
at δ 139.5 is attributed to the C2 and C11 carbon 
atoms of BP. The weak carbon signal at δ 130 owes 
to the C1, C3 and C4 carbon atoms in which nitro 
group is present in the picrate moiety. The C5 and C6 
carbon atoms of the same kind bring forth a signal at 
δ 126.4. The highly intense peak at δ 125.1 is due to 
C7, C12/C8, C13 carbon atoms of the same 
environment in benzimidazolium moiety and the 




The thermal stability and its decomposition pattern 
of BP has been established by consecutively 
employing TG/DTA analysis and the thermogram is 
shown in Fig. 4. From TG curve, it is contained that 
the title complex is stable up to 146°C and it 
decompose immediately after melting which is 
inferred that there is no inclusion of environmental 
moisture during crystallization. The decomposition 
occurs in a single stage. From the DTA curves, the 
sharp endothermic peak appearing at 146°C 
corresponds to the melting point of the material. This 
is followed by endothermic may be possible due to 
complex formation. No thermal anomaly was 
observed before the 146C, this suggests that the BP 
was stable up to 146C. 
  
DNA binding studies 
Electronic absorption spectroscopy is one of the 
most common and effective technique for 
investigation of the binding modes of organic 
compounds with CT-DNA. Compound binding 
through intercalation usually results in hypochromism 




Fig. 3 — (A) 1H NMR spectrum and (B) 13C NMR of BP 
 
 
Fig. 4 — Thermal analysis graphs of BP 
 




intercalative mode involves a strong interaction 
between the aromatic chromophore and the base pairs 
of DNA45. Absorption spectra of the BP in the 
absence and presence of CT-DNA is given in (Fig. 5). 
 
The binding mode of BP has been characterized 
through absorbance and shifts in the wavelength as a 
function of added concentration of DNA. Upon 
addition of increasing amounts of CT-DNA, a 
significant hypochromism is observed. This can be 
attributed to a strong interaction between DNA and 
compound and it is also likely that this compound 
binds to the DNA helix via intercalation. In order to 
illustrate quantitatively the consequence, the 
absorption data were analyzed to evaluate the intrinsic 
binding constant (Kb), which can be determined from 
the following equation 46-48, 
DNA/ (ɛa- ɛf) =[DNA]/ (ɛb- ɛf) + 1/Kb (ɛb- ɛf) 
where [DNA] is the concentration of DNA in base 
pairs, the apparent absorption coefficient ɛa, ɛf and ɛb 
corresponds to Aobs/[compound], the extinction 
coefficient of the free compound and the extinction 
coefficient of the compound when fully bound to 
DNA, respectively. From the plot of DNA/(ɛa- ɛf) 
versus [DNA], Kb is calculated by the ratio of slope to 
the intercept. The magnitude of intrinsic binding 
constant (Kb) value for BP is 4.9 X 10
4 M-1. From the 
above DNA binding results, it is obvious that the title 
compound has planarity and extended π system which 
lead to the possibility of DNA intercalation. 
 
Antioxidant activity 
The DPPH radical has been used to test the ability 
of compound as free radical scavenger or hydrogen 
donor to evaluate the antioxidant activity. Hence 
experiments were carried out to explore the free 
radical scavenging ability of benzimidazolium picrate 
with DPPH radical49,50 and compared with those of the 
positive control, ascorbic acid (Aca). The compound 
shows significant capacity for scavenging DPPH and 
the IC50 value (Fig. 6) indicated that it shows potent 
antioxidant activity. It also shows scavenging capacity 
beyond 83 μm/mL. The activity of BP is also found to 
be good. (Table 1)  
 
Single crystal X-ray diffraction method 
A single crystal X-ray analysis is made at 296 K 
using suitable crystals for data collection. Accurate 
lattice parameters are resoluted from least squares 
refinement of well centered reflection in the range 
2.58 θ U θ 28.30. The complex, BP belongs to the 
monoclinic system with space group P21/c. The lattice 
parameter obtained are a=9.2376(7) Å, b=11.9355(7) 
Å, c= 12.8931(7) Å, α =90.00°, β=97.811(2)°, 
γ=90.00° and the unit volume is 1408.34(16) Å3. The 
crystallographic data and structure refinements of BP 
complex are given in Table 2.  
 
The benzimidazolium ion appears in crystalline 




Fig. 5 — Electronic spectra of BP in Tris–HCl buffer upon 




Fig. 6 — Antioxidant activity of BP 
 
 [Compound] = 25 μM, [DNA] = 0–50 μΜ DNA Solvent = (95% 




Table 1 — Comparison of antioxidant activity of  
Benzimidazolium picrate (BP) with other compounds 
 




3-aminopyridium- p-toluenesulfonate51 125 
Benzimidazolium picrate 83 
Ascorbic acid  66.26 
 
 




is present as deprotonated anion. X-ray single crystal 
structure of the charge-transfer complex of 
benzimidazole with picric acid shows the presence of 
mono protonated benzimidazolium cation and gives 
the intermolecular hydrogen bonding association. The 
ORTEP diagram of BP is depicted the Fig. 7.  
 
The selected bond lengths and bond angle is given 
in Table 3, respectively. In the picrate anion, C-O 
bond distance of anion is evident for characteristic 
values with C2–O6 [1.2413(18) Å] which is 
intermediate between single and double bond 
characters. The loss of a proton from picric acid is 
confirmed by the lengthening of the C-C bonds. The 
C1-C2 and C1-C3 bond lengths are (1.447(2) Å) and 
(1.450(2) Å), respectively which deviate from the 
standard aromatic C-C bond length (1.40 Å). These 
differences are attributed to the loss of a hydroxyl 
proton at O6, leading to conversion from neutral to 
the anionic state where the negative charge is 
constrained to lie in the ring. The crystal packing 
diagram of BP is shown in Fig. 8. 
 
The picrate anion plays a vital role in forming 
hydrogen bonds with cation and stabilizing the 
structure. The degree of twisting of the nitro group 
from the benzene plane does not depend upon the C-N 
bond distance. The C-O bond length of the phenolate 
[1.248(2)°] corresponds to a partial double bond 
character implying that the negative charge located on 
the phenolate oxygen atom is delocalized. The N-O 
bond distance of the nitro groups of the trinitro-
phenolate anion are typical double bonds. 
The twist angles of the three nitro group from the 
benzene plane of the picrate ion are (O1-N1-O5, 
121.10(14) Å), (O7-N2-O2, 121.68(17) Å) and (O3-
N3-O4, 123.24(17) Å). Analysis of the picrate ion 
show that the ortho nitro groups in general, deviate 
away from the benzene plane due to steric interactions 
with the phenol group at C5 but para nitro group lies 
in the benzene plane. Deviation from the normal 
behaviour arises in many structures as a result of 
crystal packing criteria which involve N-H...O and C-
H....O hydrogen bonds with the nitro group O atoms. 
 
The formation of intermolecular hydrogen bond N-
H....O and C-H....O in crystal structure lead to 
supramolecular networking. The hydrogen bonded 








Fig. 8 — Crystal packing diagram of BP 
 
 
Table 2 — Crystallographic data and structure refinement 
parameters of  Benzimidazolium picrate (BP) complex 
Empirical formula C13 H9 N5 O7 
Formula weight 347.25 
Temperature 296 (2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21/c 
 
Cell dimensions 
a = 9.2376(7)Å, α =90.00° 
b = 11.9355(7) Å, β = 97.811(2)° 
c = 12.8931(7) Åγ = 90.00° 
Volume 1408.34(16) Å3 
Z 4 
Density (calculated) 1.638 mg/m-3 
Absorption coefficient 0.137 mm-1 
F(000) 712 
Crystal size 0.40 × 0.35 × 0.30 mm-1 
Reflections collected 11222 
Range for data collection 
(deg) 
2.58-28.30 ° 
Number parameters 227 
Absorption correction Semi-empirical from equivalents 
Max and min. transmission 0.9602 and 0.9474 
Limiting indices h, k, l -12/8, -15/15, -17/15 
Refinement method Full-matrix least squares on F2 
Goodness of F2 1.017 
 




joined to the anion part via extended hydrogen 
bonding. In crystal structure the cation and anion 
linking by strong N-H...O and C-H....O hydrogen 
bonding. The combination of all type of inter-
molecular hydrogen forms three dimensional networks. 
This hydrogen bonding link layer of cation with the 
layer anion form straight chain along in the b axis. 
 
Conclusions 
A novel organic charge transfer crystal of 
Benzimidazolium picrate was synthesized and 
successfully grown by the slow evaporation solution 
growth technique at ambient temperature. The single 
crystal analysis indicated that the crystal belongs to 
monoclinic with P21/c space group. The CT complex 
is found to be biologically significant with regards to 
its DNA binding. The radical scavenging activity 
showed that the CT complex possesses the greater 
activity against DPPH radical. FTIR was substantial 
the presence of functional group, especially +NH 
stretching vibration at 3155 cm-1. The UV spectrum 
confirmed the formation of CT complex. TG and 
DTA analysis inferred the thermal stability of the 
synthesized complex. The proton and carbon positions 
were analyzed by NMR spectra which establish 
molecular structure of the crystal. 
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